Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic DermatitisPRNewsWire • 06/28/21
Hoth Therapeutics Announces Sponsored Research Agreement with Washington University for Novel Alzheimer's Therapeutic HT-ALZPRNewsWire • 06/07/21
Hoth Therapeutics Shares Positive Preclinical Results of Novel HT-KIT TherapeuticPRNewsWire • 06/03/21
Hoth Therapeutics Plans Shareholder Presentation on HT-KIT Therapeutic's Preclinical Results for Rare CancersPRNewsWire • 06/01/21
Hoth Therapeutics Announces Participation at the American Society of Clinical Oncology (ASCO) Annual MeetingPRNewsWire • 05/24/21
HOTH Therapeutics (NASDAQ: HOTH): Developing Life-Changing Drugs for Rare Cancers and DiseasesBenzinga • 05/18/21
Hoth Therapeutics Provides Shareholder Update on Novel Endocannabinoid Therapeutic for Cutaneous Lupus ErythematosusPRNewsWire • 05/13/21
Hoth Therapeutics and Virginia Commonwealth University Expand Research Agreement for COVID-19 TherapeuticPRNewsWire • 05/05/21
Hoth Therapeutics Announces Development of HT-KIT to Treat Multiple Orphan Diseases, Including Rare CancersPRNewsWire • 05/03/21
Hoth Therapeutics' First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is UnderwayPRNewsWire • 04/22/21
Hoth Therapeutics' mRNA Frame Shifting Therapeutic Inhibits Tumor Growth, Animal Study ShowsBenzinga • 04/20/21
Hoth Therapeutics Announces its mRNA Frame Shifting Therapeutic Significantly Inhibits Tumor Growth in Mast Cell-Derived CancersPRNewsWire • 04/20/21
Hoth Therapeutics Completes HT-001 Formulation Development for Upcoming Cancer Patient Clinical TrialPRNewsWire • 04/12/21
Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer PatientsPRNewsWire • 04/06/21
Hoth Therapeutics, Inc. Announces Notice of Allowance for a New Patent Application Related to A Method for Inhibiting Formation of a BiofilmPRNewsWire • 04/05/21
Hoth Therapeutics' Partner Voltron Therapeutics Reports Encouraging Preclinical Data From COVID-19 Vaccine CandidateBenzinga • 03/24/21
HOTH Stock: The News That Has Biopharma Hoth Therapeutics Shooting Higher TodayInvestorPlace • 03/23/21
Hoth Therapeutics Stock Rallies As Lead Peptide Candidate Shows Encouraging Preclinical Antiviral Activity Against COVID-19Benzinga • 03/23/21
Hoth Therapeutics Announces Positive Preclinical Results for Novel COVID-19 TherapeuticPRNewsWire • 03/23/21
Hoth Therapeutics CEO, Robb Knie, Featured on the RedChip Money Report on Bloomberg TV this Saturday, March 20thPRNewsWire • 03/19/21
Hoth Therapeutics Partners with University of Cincinnati to Perform Critical Studies for Streamlined Development of Novel Antibiotic HT-006PRNewsWire • 03/17/21
Hoth Therapeutics Executes Agreement to Assess the Effect of HT-003 Therapeutic Platform on Ulcerative Colitis and Crohn's DiseasePRNewsWire • 03/11/21